Clinical trials: Leukemia, Myeloblastic, Acute
Non-Hodgkin's Lymphoma, Leukemia
Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT
One of two different doses of thymoglobulin will allow bone marrow engraftment with minimal Graft-versus-Host Disease and allow adequate immune response to allow the transplanted stem cells to replace the tumor cells.
- Conditions
- Non-Hodgkin's Lymphoma, Leukemia, Multiple Myeloma, Acute Myeloid Leukemia
- Trial name
- NCT00709592
- Testing
- Thymoglobulin, Total-Body Irradiation, Allogeneic PBSCT or BMT
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Virginia Commonwealth University
Leukemia, Myelodysplasia
Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia
Unrelated Cord Blood (UCB) transplant in children is a viable stem cell transplant modality for patients with leukemia and myelodysplasia.
- Conditions
- Leukemia, Myelodysplasia, Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia
- Trial name
- NCT02007863
- Testing
- Umbilical Cord Blood Transfusion, Fludarabine, Busulfan
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- University of Miami
Leukemia
S9031-S9126-S9333-S9500-A, Studying Bone Marrow and Blood Samples From Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of bone marrow and blood in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00899171
- Testing
- DNA analysis, DNA methylation analysis, RNA analysis
- Volunteers
- 251 people
- Sponsor
- SWOG Cancer Research Network
AML - Acute Myeloid Leukemia, MDS (Myelodysplastic Syndrome)
Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders
A significant number of patients with hematologic malignancies need a hematopoietic stem cell transplant (HSCT) to be cured. Only about 50% of these patients have a fully matched donor, the remaining patients will require an HSCT…
- Conditions
- AML - Acute Myeloid Leukemia, MDS (Myelodysplastic Syndrome), Mixed Phenotype Acute Leukemia, NHL - Non-Hodgkin's Lymphoma
- Trial name
- T-allo10 (NCT03198234)
- Testing
- T-allo10
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Roncarolo, Maria Grazia, MD
Leukemia, Myelodysplastic Syndromes
Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow…
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00005863
- Testing
- filgrastim, cytarabine, daunorubicin hydrochloride
- Where
- United Kingdom
- Sponsor
- Medical Research Council
Acute Myeloid Leukemia
Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
A treatment cycle is 28 days. Tagraxofusp will be administered at 9 mcg/kg IV over 15 minutes (-5 or +15 minutes) daily for 3 consecutive days (or 3 doses over a period not to exceed 10 days if postponement is required to allow…
- Trial name
- TAGALONG (NCT05442216)
- Testing
- Tagraxofusp, Azacitidine, Venetoclax
- Where
- 7 sites in United States
- Volunteers
- 53 people
- Sponsor
- Joshua Zeidner
Cancer
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
RATIONALE: Suberoylanilide hydroxamic acid may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
- Trial name
- NCT00045006
- Testing
- vorinostat
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Relapsed Adult AML, Refractory AML
Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
This is an open-label phase I study designed to evaluate the safety of venetoclax-navitoclax with cladribine-based salvage therapy.
- Trial name
- NCT06007911
- Testing
- Navitoclax Dose Level -1, Navitoclax Dose Level 0, Navitoclax Dose Level 1
- Where
- United States
- Sponsor
- Medical College of Wisconsin
High Risk MDS or AML Patients
Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox)
The purpose of this trial is to examine the hematologic response rate of Exjade® in patients with AML and high risk MDS and chronic iron overload from blood transfusions.
- Trial name
- NCT02233504
- Testing
- Exjade® (deferasirox, ICL670)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Acute Myeloid Leukemia
Characterization of T-cell Repertoire in Patients With Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant
This research trial studies characterization of T-cell repertoire through next-generation sequencing in patients with acute myeloid leukemia undergoing stem cell transplant.
- Trial name
- NCT03921047
- Testing
- Biospecimen Collection, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- University of Southern California
Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations.
- Conditions
- Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation, Refractory AML, AML With Mutated NPM1
- Trial name
- NCT05735184
- Testing
- Ziftomenib, Venetoclax, Azacitidine
- Where
- 44 sites in United States
- Volunteers
- 420 people
- Sponsor
- Kura Oncology, Inc.
Standard Therapy, Non-standard Therapy
SD vs. NSD Therapy in Elderly AML
It is known that treatment outcome could be positively associated with treatment intensity. However, tolerance of chemotherapy decreases in the elder, some patients could not tolerate standard (SD) therapy and even died of side…
- Trial name
- NCT03733834
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Acute Myeloid Leukemia, Fatigue
Individualized Music Listening in Acute Leukemia Patients With Fatigue
The objective of this study is to assess the efficacy of employing music therapy in alleviating fatigue and medical laboratory values among patients with acute myeloid leukemia.
- Trial name
- NCT06286332
- Testing
- Music Therapy
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Chang Gung University
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant
Primary: To determine the maximum tolerated dose and schedule of decitabine when administered as maintenance therapy after allogeneic hematopoietic stem cell transplantation (alloHSCT) performed for AML or high-risk MDS.
- Trial name
- AML MDS (NCT00986804)
- Testing
- Decitabine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Washington University School of Medicine
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer
RATIONALE: Methadone, morphine, or oxycodone may help relieve pain caused by cancer. It is not yet known whether methadone is more effective than morphine or oxycodone in treating pain in patients with cancer.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00726830
- Testing
- methadone hydrochloride, morphine sulfate, oxycodone hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Myelodysplastic Syndromes, Acute Myeloid Leukemia
BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS
To assess the efficacy, and safety of BST-236 in patients unfit for intensive chemotherapy with AML or HR MDS that failed or relapsed following first line therapy
- Trial name
- NCT04827719
- Testing
- BST-236
- Where
- 17 sites in France
- Volunteers
- 38 people
- Sponsor
- Groupe Francophone des Myelodysplasies
Acute Myelogenous Leukemia
Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia
In patients with Core Binding Factors Acute Myelogenous Leukemia, the level of Minimal Residual Disease after chemotherapy is predictive of relapse.
- Trial name
- DasaCBF (NCT02113319)
- Testing
- dasatinib
- Where
- France
- Volunteers
- 27 people
- Sponsor
- University Hospital, Angers
Leukemia, Myeloid, Acute
Randomised Prospective Comparison of the NMA Allograft and the Traditional Allograft in Acute Myeloid Leukaemia
The allograft of marrow in its technique of reference (myélo-ablative (MA) condition by cyclophosphamide and total body irradiation (TBI) with strong amounts) therapeutic is recognized acute myeloid leukaemia (AML) of the adult…
- Trial name
- NCT00224614
- Testing
- Allogenic transplantation
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Leukemia Acute Myeloid - AML
Study With Tocilizumab in Combination With Venetoclax and Azacitidine Chemotherapy in Patients With Acute Myeloid Leukemia
This is a phase 1, open label, interventional, single center, in patients with Acute Myeloid Leukemia (AML). This study will investigate dose escalation of tocilizumab in combination with venetoclax and azacitidine chemotherapy.
- Trial name
- TOCIVENA (NCT07392814)
- Testing
- increase dose of tocilizumab
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Nantes University Hospital
Acute Myeloid Leukemia
Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia
Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomized to receive gilteritinib or midostaurin during induction and consolidation.
- Trial name
- NCT03836209
- Testing
- Gilteritinib, Midostaurin, Daunorubicin
- Where
- 44 sites in United States
- Volunteers
- 181 people
- Sponsor
- PrECOG, LLC.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.